Human immunodeficiency virus-1 Tat protein up-regulates interleukin-6 and interleukin-8 expression in human breast cancer cells

Inflammation Research

Volumn 54, Issue 9, 2005, Pages 380-389

  Lee, Y W ^a   Hirani, A A ^a   Kyprianou, N ^b   Toborek, M ^b  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

AIDS; Inflammation; MDA MB 231; Metastasis; NF B

Indexed keywords

GELATINASE B; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; TRANSACTIVATOR PROTEIN; DNA; PROTEIN SYNTHESIS INHIBITOR; RECOMBINANT PROTEIN; TAT PROTEIN (1 72), HIV 1; TAT PROTEIN (1-72), HIV-1; TOSYLPHENYLALANYL CHLOROMETHYL KETONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPOSURE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; METASTASIS POTENTIAL; MICROENVIRONMENT; MOLECULAR MECHANICS; PROTEIN DETERMINATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; TRANSCRIPTION REGULATION; UPREGULATION; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DNA; GENE PRODUCTS, TAT; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; PROTEIN SYNTHESIS INHIBITORS; RECOMBINANT PROTEINS; RNA, MESSENGER; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; TRANS-ACTIVATION (GENETICS); UP-REGULATION;

EID: 32944477173     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-005-1371-8     Document Type: Article

References (73)

1. Saiki I. Cell adhesion molecules and cancer metastasis. Jpn J Pharmacol 1997; 75: 215-42.
2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-15.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
4. Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, et al. Expression of interleukin-1β in human breast carcinoma. Cancer 1997; 80: 421-34.
5. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 1997; 43: 211-5.
6. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999; 19: 1427-32.
7. De Larco JE, Wuertz BRK, Rosner KA, Erickson SA, Gamache DE, Manivel JC, et al. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 2001; 158: 639-6.
8. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002; 106: 1420-5.
9. Hutchinson JF. The biology and evolution of HIV. Annu Rev Anthropol 2001; 30: 85-108.
10. Williams KC, Hickey WF. Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 2002; 25: 537-562.
11. Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer 2002; 2: 373-82.
12. Dal Maso L, Franceschi S, Polesel J, Braga C, Piselli P, Crocetti E, et al. Risk of cancer in persons with AIDS in Italy, 1985-1998. Br J Cancer 2003; 89: 94-100.
13. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 1823-30.
14. El-Rayes BF, Barenji K, Schuman P, Philip PA. Breast cancer in women with human immunodeficiency virus infection: implications for diagnosis and therapy. Breast Cancer Res Treat 2002; 76: 111-6.
15. Guth AA. Breast cancer and HIV: what do we know? Am Surg 1999; 65: 209-11.
16. Guth AA. Breast cancer and human immunodeficiency virus infection: issues for the 21st century. J Womens Health (Lachmt) 2003; 12: 227-32.
17. Voutsadakis IA, Silverman LR. Breast cancer in HIV-positive women: a report of four cases and review of the literature. Cancer Invest 2002; 20: 452-7.
18. Jones M, Olafson K, Del Bigio MR, Peeling J, Nath A, Intraventricular injection of human immunodeficiency virus type 1 (HIV-1) Tat protein causes inflammation, gliosis, apoptosis, and ventricular enlargement. J Neuropathol Exp Neurol 1998; 57: 563-70.
19. Ma M, Nath A. Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J Virol 1997; 71: 2495-9.
20. Toborek M, Lee YW, Pu H, Malecki A, Flora G, Garrido R, et al. HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem 2003; 84: 169-79.
21. Pu H, Flora G, Lee YW, Nath A, Hennig B, Toborek M. HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol Cell Neurosci 2003; 24: 224-37.
22. Flora G, Pu H, Lee YW, Ravikumar R, Nath A, Hennig B, et al. Proinflammatory synergism of ethanol and HIV-1 Tat protein in brain tissue. Exp Neurol 2005; 191: 2-12.
23. Hayashi K, Pu H, Tian J, Andras IE, Lee YW, Hennig B, et al. HIV-Tat protein induces P-glycoprotein expression in brain microvascular endothelial cells. J Neurochem 2005, in press.
24. Andras IE, Pu H, Deli MA, Nath A, Hennig B, Toborek M. HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res 2003; 74: 255-65.
25. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-Tat and gp 120. Nature 1995; 375: 497-500.
26. Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, Murphy PM, et al. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci USA. 2000; 97: 11466-71.
27. Lee YW, Eum SY, Nath A, Toborek M. Estrogen-mediated protection against HIV Tat protein-induced inflammatory pathways in human vascular endothelial cells. Cardiovasc Res 2004; 63: 139-48.
28. Andras IE, Pu H, Tian J, Deli MA, Nath A, Hennig B, et al. Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells. J Cereb Blood Flow Metab 2005, in press.
29. Nath A, Conant K, Chen P, Scott C, Major EO. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem 1999; 274: 17098-102.
30. Deng X, Li H, Tang YW. Cytokine expression in respiratory syncytial virus-infected mice as measured by quantitative reverse-transcriptase PCR. J Virol Methods 2003; 107: 141-6.
31. -ÄÄCT method. Methods 2001; 25: 402-8.
32. Beg AA, Finco TS, Nantermet PV, Baldwin AS Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκBα: a mechanism for NF-κB activation. Mol Cell Biol 1993; 13: 3301-10.
33. Toborek M, Lee YW, Kaiser S, Hennig B. Measurement of inflammatory properties of fatty acids in human endothelial cells. Methods Enzymol 2002; 352: 198-219.
34. Kaiser S, Toborek M. Liposome-mediated high-efficiency transfection of human endothelial cells. J Vasc Res 2001; 38: 133-43.
35. Abate A, Schroder H. Protease inhibitors protect macrophages from lipopolysaccharide-induced cytotoxicity: possible role for NF-κB. Life Sci 1998; 62: 1081-8.
36. D'Acquisto F, luvone T, Rombola L, Sautebin L, Di Rosa M, Carnuccio R. Involvement of NF-κB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages. FEBS Lett 1997; 418: 175-8.
37. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997; 11: 1421-31.
38. Frankel AD, Young JA. HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 1998; 67: 1-25.
39. Chen P, Mayne M, Power C, Nath A. The Tat protein of HIV-1 induces tumor necrosis factor-α production. Implications for HIV-1-associated neurological diseases. J Biol Chem 1997; 272: 22385-8.
40. Gibellini D, Zauli G, Re MC, Milani D, Furlini G, Caramelli E, et al. Recombinant human immunodeficiency virus type-1 (HIV-1) Tat protein sequentially up-regulates IL-6 and TGF-β1 mRNA expression and protein synthesis in peripheral blood monocytes. Br J Haematol 1994; 88: 261-7.
41. Sawaya BE, Thatikunta P, Denisova L, Brady J, Khalili K, Amini S. Regulation of TNF-α and TGFβ-1 gene transcription by HIV-1 Tat in CNS cells. J Neuroimmunol 1998; 87: 33-42.
42. Bruce-Keller AJ, Barger SW, Moss NI. Pham JT, Keller JN, Nath A. Pro-inflammatory and pro-oxidant properties of the HIV protein Tat in a microglial cell line: attenuation by 17β-estradiol. J Neurochem 2001; 78: 1315-24.
43. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993; 52: 232-4.
44. Hyams JS, Fitzgerald JE, Treem WR, Wyzga N, Kreutzer, DL. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 1993; 104: 1285-92.
45. Dunbar CE, Nienhuis AW. Multiple myeloma. New approaches to therapy. JAMA 1993; 269: 2412-6.
46. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 1993; 53: 2118-22.
47. Watson JM, Berek JS, Martinez-Maza O. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol 1993; 49: 8-15.
48. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161: 182-7.
49. Breen EC, Rezai AR, Nakajima K, Beall GN, Mitsuyasu RT, Hirano T, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990; 144: 480-4.
50. Gallo P, Frei K, Rordorf C, Lazdins J, Tavolato B, Fontana A. Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluid. J Neuroimmunol 1989; 23: 109-16.
51. Ambrosino C, Ruocco MR, Chen X, Mallardo M, Baudi F, Trematerra S, et al. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein β (NF-IL6) transcription factors. J Biol Chem 1997; 272: 14883-92.
52. Matsushima K, Baldwin ET, Mukaida N. Interleukin-8 and MCAF: novel leukocyte recruitment and activating cytokines. Chem Immunol 1992; 51: 236-65.
53. Miller MD, Kranger MS. Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit Rev Immunol 1992; 12: 17-46.
54. Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, et al. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 2003; 22: 256-65.
55. Greene GF, Kitadai Y, Pettaway CA, von Eschenbach AC, Bucana CD, Fidler IJ. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 1997; 150: 1571-82.
56. Kim SJ, Uehara H, Karashima T, Mccarty M, Shih N, Fidler, IJ. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 2001; 3: 33-42.
57. Kitadai Y, Haruma K, Mukaida N, Ohmoto Y, Matsutani N, Yasui W, et al. Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res 2000; 6: 2735-40.
58. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994; 54: 3242-7.
59. Xu L, Fidler IJ. Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res 2000; 60: 4610-6.
60. Matsumoto T, Miike T, Nelson RP, Trudeau WL, Lockey RF, Yodoi J. Elevated serum levels of IL-8 in patients with HIV infection. Clin Exp Immunol 1993; 93: 149-51.
61. Lane BR, Lore K, Bock PJ, Andersson J, Coffey MJ, Strieter RM, et al. Interleukin-8 stimulates human immunodeficiency virus type 1 replication and is a potential new target for antiretroviral therapy. J Virol 2001; 75: 8195-202.
62. Ott M, Lovett JL, Mueller L, Verdin E. Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-κB factors. J Immunol 1998; 160: 2872-80.
63. Lane BR, Liu J, Bock PJ, Schols D, Coffey MJ, Stricter RM, et al. Interleukin-8 and growth-regulated oncogene α mediate angiogenesis in Kaposi's sarcoma. J Virol 2002; 76: 11570-83.
64. Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, et al. Transforming growth factor-β1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NK-κB, JNK, and Ras signaling pathways. Oncogene 2003; 22: 4314-32.
65. Conant K, Ma M, Nath A, Major EO. Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF-κB binding and protein kinase C activity in primary human astrocytes. J Virol 1996; 70: 1384-9.
66. Cota-Gomez A, Flores NC, Cruz C, Casullo A, Aw TY, Ichikawa H, et al. The human immunodeficiency virus-1 Tat protein activates human umbilical vein endothelial cell E-selectin expression via an NF-κB-dependent mechanism. J Biol Chem 2002; 277: 14390-9.
67. Heyen JR, Ye S, Finck BN, Johnson RW. Interleukin (IL)-10 inhibits IL-6 production in microglia by preventing activation of NF-κB. Brain Res Mol Brain Res 2000; 77: 138-47.
68. Ruetten H, Thiemermann C, Perretti M. Upregulation of ICAM-1 expression on J774.2 macrophages by endotoxin involves activation of NF-κB but not protein tyrosine kinase: comparison to induction of iNOS. Mediators Inflamm 1999; 8: 77-84.
69. Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 2002; 52: 255-64.
70. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000; 10: 415-33.
71. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
72. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix proteinases: structures, evolution, and diversification. FASEB J 1998; 12: 1075-95.
73. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996; 7: 147-54.